Genmab Q2 & conference call – key takeaway

In this and the coming quarters Genmab is focusing on its late stage assets as they progress toward an approval for Daratumumab and expansion of the label for Arzerra. The revenue and cost side of the company is as expected, there are no crazy things going around in the balancesheet. But there were some eyeopening information from…

Vores uafhængige analyser er tilgængelig mod betaling / This content is for Peter Hildebrandt Fundmanager Subscription and Premium – ALL fundmanagers members only.
Log In Register